Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children30810.24287/1726-1708-2020-19-1-68-78ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИNon-invasive prediction of an unfavorable histological variant in patients with neuroblastic tumors using the quantitative and semiquantitative assessment of ¹²³I-MIBG uptakeНеинвазивное определение неблагоприятного гистологического варианта у детей с нейрогенными опухолями по накоплению ¹²³I-МЙБГ с использованием полуколичественной и количественной оценокhttps://orcid.org/0000-0002-7427-4560KailashA.КайлашA.
Russian Federation

Moscow

https://orcid.org/0000-0003-3990-8879KireevaE. D.КирееваЕ. Д.
Russian Federation

Moscow

https://orcid.org/0000-0002-9176-2347VdovinaI. S.ВдовинаИ. С.
Russian Federation

Moscow

https://orcid.org/0000-0003-3792-1682YadgarovM. Ya.ЯдгаровМ. Я.
Russian Federation

Moscow

https://orcid.org/0000-0002-3767-4477ShamanskayaT. V.ШаманскаяТ. В.
Russian Federation

Moscow

https://orcid.org/0000-0002-9375-7517RoshinV. Yu.РощинВ. Ю.
Russian Federation

Moscow

https://orcid.org/0000-0002-3704-8783KachanovD. Yu.КачановД. Ю.
Russian Federation

Moscow

https://orcid.org/0000-0002-6158-2222LikarYu. N.ЛикарьЮ. Н.
Russian Federation

MD., PhD, Head of Nuclear Medicine Department,

117997, Moscow, Samory Mashela st., 1

д-р мед. наук, заведующий отделением ПЭТ и радионуклидной диагностики,

117997, Москва, ГСП-7, ул. Саморы Машела, 1

Yury.Likar@fccho-moscow.ruDmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России2803202019168782803202028032020Copyright ©; 2020, «D. Rogachev NMRCPHOI»Copyright ©; 2020, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2020«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/308

¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy is widely used for the detection and staging of neuroblastoma. Risk-adapted treatment in patients with neuroblastic tumors is based on many clinical and genetic factors including histopathology. Purpose: non-invasive prediction of an unfavorable histological variant in patients with neuroblastic tumors using quantitative assessment of ¹²³I-MIBG uptake. This study was approved by the Independent Ethical Committee and the Academic Council of Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation. 96 patients were included in this retrospective study. ¹²³I-MIBG-scintigraphy including whole body planner images and SPECT/CT were performed for all patients before any type of treatment. Semiquantitative and quantitative assessment of ¹²³I-MIBG uptake were calculated and analyzed. Out of 96 patients: 54 with neuroblastoma (NB), 28 with ganglioneuroblastoma (GNB) and 14 with ganglioneuroma (GN). The average values of TLCRR and SUVmax for NB were 5.67 and 7.5, for GNB – 2.58 and 3.1 and for GN – 1.48 and 1.85, respectively. A centile analysis was carried out for all groups. SPECT/CT in combination with modern software allows semiquantitative and quantitative assessment of ¹²³I-MIBG uptake in neuroblastic tumor. The TLCRR and SUVmax can be used separately as well as in combination with NSE for prediction of histological variant. 

Сцинтиграфия с ¹²³I-метайодобензилгуанидином (¹²³I-МЙБГ) широко используется для диагностики и стадирования у пациентов с нейрогенными опухолями. Лечение пациентов с нейробластомой (НБ) зависит от группы риска и базируется на многих клинических и генетических факторах, включая гистологический вариант опухоли. Цель исследования: неинвазивное определение неблагоприятного гистологического варианта по интенсивности накопления ¹²³I-МЙБГ в нейрогенной опухоли. Данное исследование одобрено Независимым этическим комитетом и утверждено решением Ученого совета НМИЦ ДГОИ им. Дмитрия Рогачева Минздрава России. В ретроспективное исследование включили 96 пациентов с впервые выявленной нейрогенной опухолью. На этапе инициальной диагностики всем пациентам выполнили сцинтиграфию с ¹²³I-МЙБГ с протоколом ОФЭКТ/КТ. Полуколичественный (TLCRR) и количественный (SUVmax) методы оценки были использованы для получения количественных значений интенсивности накопления ¹²³I-МЙБГ в первичной опухоли. Среди 96 МЙБГ-позитивных пациентов 54 были с НБ, 28 – с ганглионейробластомой (ГНБ) и 14 – с ганглионейромой (ГН). Средние значения TLCRR и SUVmax при НБ составили 5,67 и 7,5; при ГНБ – 2,58 и 3,1; при ГН – 1,48 и 1,85 соответственно. Центильный анализ показал, с какой вероятностью значение каждого параметра для конкретного типа опухоли не превысит рассчитанное. Использование протокола ОФЭКТ/КТ и современного программного обеспечения позволяют выполнять полуколичественную и количественную оценки интенсивности накопления ¹²³I-МЙБГ в опухоли, а полученные значения TLCRR и SUVmax как раздельно, так и в комбинации с нейронспецифической энолазой могут быть использованы для неинвазивного определения неблагоприятного гистологического варианта. 

neuroblastomaganglioneuroblastomaganglioneuromascintigraphymetaiodobenzylguanidine (¹²³I-MIBG)SUVmaxTLCRRнейробластомаганглионейробластомаганглионейромасцинтиграфияметайодобензилгуанидин (¹²³I-МЙБГ)SUVmaxTLCRR1. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86 (2): 349–63.Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86 (2): 349–63.2. Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86 (2): 364–72.Shimada H., Ambros I.M., Dehner L.P., Hata J., Joshi V.V., Roald B., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86 (2): 364–72.3. Louis C.U., Shohet J.M. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 2015; 66: 49–63.Louis C.U., Shohet J.M. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med 2015; 66: 49–63.4. Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27 (2): 298–303.Monclair T., Brodeur G.M., Ambros P.F., Brisse H.J., Cecchetto G., Holmes K., et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27 (2): 298–303.5. Matthay K.K., Perez C., Seeger R.C., Brodeur G.M., Shimada H., Atkinson J.B., et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998; 16 (4): 1256–64.Matthay K.K., Perez C., Seeger R.C., Brodeur G.M., Shimada H., Atkinson J.B., et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998; 16 (4): 1256–64.6. Okuyama C., Ushijima Y., Watanabe K., Sugihara H., Nishimura T. Iodine-123- MIBG scintigraphy in neuroblastoma; relationship between the intensity of uptake and tumor characteristics. Kaku Igaku 1999; 36 (8): 827–34.Okuyama C., Ushijima Y., Watanabe K., Sugihara H., Nishimura T. Iodine-123- MIBG scintigraphy in neuroblastoma; relationship between the intensity of uptake and tumor characteristics. Kaku Igaku 1999; 36 (8): 827–34.7. Fendler W.P., Melzer H.I., Walz C., von Schweinitz D., Coppenrath E., Pfluger T. High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology. Eur J Nucl Med Mol Imaging 2013; 40 (11): 1701–10.Fendler W.P., Melzer H.I., Walz C., von Schweinitz D., Coppenrath E., Pfluger T. High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology. Eur J Nucl Med Mol Imaging 2013; 40 (11): 1701–10.8. Fendler W.P., Wenter V., Thornton H.I., Ilhan H., von Schweinitz D., Coppenrath E. Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy. PLoS One 2015; 10 (7): e0132809.Fendler W.P., Wenter V., Thornton H.I., Ilhan H., von Schweinitz D., Coppenrath E. Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy. PLoS One 2015; 10 (7): e0132809.9. Bailey D.L., Willowson K.P. An evidencebased review of quantitative SPECT imaging and potential clinical applica tions. J Nucl Med 2013; 54 (1): 83–9.Bailey D.L., Willowson K.P. An evidencebased review of quantitative SPECT imaging and potential clinical applica tions. J Nucl Med 2013; 54 (1): 83–9.10. McDougald W.A., Miyaoka R.S., Alessio A.M., Harrison R.L., Lewellen T.K. A study of SPECT/CT camera stability for quantitative imaging. EJNMMI Phys 2016; 3: 14.McDougald W.A., Miyaoka R.S., Alessio A.M., Harrison R.L., Lewellen T.K. A study of SPECT/CT camera stability for quantitative imaging. EJNMMI Phys 2016; 3: 14.11. Jacobson A.F., Deng H., Lombard J., Lessig H.J., Black R.R. 123I-metaiodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010; 95 (6): 2596–606.Jacobson A.F., Deng H., Lombard J., Lessig H.J., Black R.R. 123I-metaiodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010; 95 (6): 2596–606.12. Sharp S.E., Gelfand M.J., Shulkin B.L. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med 2011; 41 (5): 345–53.Sharp S.E., Gelfand M.J., Shulkin B.L. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med 2011; 41 (5): 345–53.13. Sharp S.E., Trout A.T., Weiss B.D., Gelfand M.J. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics 2016; 36 (1): 258–78.Sharp S.E., Trout A.T., Weiss B.D., Gelfand M.J. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics 2016; 36 (1): 258–78.14. Vik T.A., Pfluger T., Kadota R., Castel V., Tulchinsky M., Farto J.C., et al. (123) I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52 (7): 784–90.Vik T.A., Pfluger T., Kadota R., Castel V., Tulchinsky M., Farto J.C., et al. (123) I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52 (7): 784–90.15. Matthay K.K., Shulkin B., Ladenstein R., Michon J., Giammarile F., Lewington V. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102 (9): 1319–26.Matthay K.K., Shulkin B., Ladenstein R., Michon J., Giammarile F., Lewington V. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102 (9): 1319–26.16. Decarolis B., Schneider C., Hero B., Simon T., Volland R., Roels F., et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol 2013; 31 (7): 944–51.Decarolis B., Schneider C., Hero B., Simon T., Volland R., Roels F., et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol 2013; 31 (7): 944–51.17. Brans B., Laureys G., Schelfhout V., Wiele C.V., Potter C.R., Dhooge C. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo. Eur J Nucl Med 1998; 25 (2): 144–9.Brans B., Laureys G., Schelfhout V., Wiele C.V., Potter C.R., Dhooge C. Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo. Eur J Nucl Med 1998; 25 (2): 144–9.18. Kluge R., Chavdarova L., Hoffmann M., Kobe C., Malkowski B., Montravers F., et al. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma. PLoS One 2016; 11 (3): e0149072.Kluge R., Chavdarova L., Hoffmann M., Kobe C., Malkowski B., Montravers F., et al. Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma. PLoS One 2016; 11 (3): e0149072.19. Cecchetto G., Mosseri V., De Bernardi B., Helardot P., Monclair T., Costa E. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23 (33): 8483–9.Cecchetto G., Mosseri V., De Bernardi B., Helardot P., Monclair T., Costa E. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23 (33): 8483–9.20. Качанов Д.Ю., Шаманская Т.В., Коновалов Д.М., Ликарь Ю.Н., Рощин В.Ю., Муфтахова Г.М. и соавт. Ганглионейрома у детей. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2014; 13 (3): 33–41.Качанов Д.Ю., Шаманская Т.В., Коновалов Д.М., Ликарь Ю.Н., Рощин В.Ю., Муфтахова Г.М. и соавт. Ганглионейрома у детей. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2014; 13 (3): 33–41.